Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07767019

Climate Change Trends and Their Impact on the Seasonal Upper Respiratory Tract Disease Burden

Investigators assume that global climate changes can influence upper respiratory tract infection peak prevalence, which may have significant clinical implication, for example, by adjusting seasonal Influenzas' vaccine timing. Therefore, the investigators will collect data from electronic medical database about patients tested positive for winter seasonal respiratory tract viruses from 2022 and compare the incidence to the meteorological profile of that season.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The seasonal cycle of respiratory viral diseases has been widely recognized for thousands of years, as annual epidemics of the common cold and influenza hit the human population like clockwork in temperate regions during winter. Many explanations for this phenomenon appear in the literature. Huang et al. reported in 2017 a decrease in Influenza incidence while average temperatures increased in Queensland, Australia. Weather variability appears to be more influential on seasonal influenza transmission among younger age groups (0-14). Not only is the temperature relevant, but all meteorological parameters also vary. For example, Qi et al. found that both low and high absolute humidity might increase influenza risk in China, and the relationship varies geographically.

The meteorological service in Israel reports a marked increase in temperature when comparing 2006-2020 to 1964-1979 and 1995-2009 across all seasons. The average warming rate from 1964-1979 to 2006-2020 is approximately 1.5°C, highlighting a notable temperature difference.

The investigators assume that global climate changes can influence Influenza peak prevalence, which may have significant clinical implication by adjusting seasonal Influenzas' vaccine timing.

The study will include identification of all patients who tested positive for URT infection with seasonal virus (Influenza, RSV, Rhinovirus, Human MetaPneumoVirus, ParaInflunza) via respiratory PCR since 2022, whether in the emergency department or during hospitalization. This will be followed by a review of medical records to extract baseline data: age, sex, weight, underlying medical conditions, and the need for hospitalization, intensive care admission, mechanical ventilation, vasopressors, or renal replacement therapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patient with a positive nasopharyngeal swab for a respiratory virus

Exclusion criteria

  • No medical record available

Treatment and study plan

No Intervention: Observational Cohort

Other

No intervention, observational retrospective study.

Primary outcomes

  1. Incidence

    Time frame: 4 winter seasons, from 2022 to 2026.

    Examining the incidence of severe upper respiratory tract illness (requiring hospital visits) in relation to weather changes over the last four seasons.

Secondary outcomes

  1. Morbidity

    Time frame: 4 winter seasons, 2022 to 2026.

    Analysis of winter morbidity trends among patients presenting to the hospital with Influenza. Including severity of illness (need for ICU admission, mechanical ventilation and/or inotropes assistance).

  2. Mortality

    Time frame: 4 winter seasons 2022-2026

    Analysis of winter mortality trends among patients presenting to the hospital with Influenza. Including mortality during hospitalization or within 30 days.

  3. recurrence

    Time frame: 4 winter seasons, 2022-2026

    Analysis of upper respiratory tract infection recurrence trends among patients presenting to the hospital with Influenza. Including recurrent admission within 30 days.

Study contacts

Contact information is provided by the study sponsor or research team.

Daniel leshin Carmel Head of Infection Control and Prevention, MD

CONTACT

[email protected]

+972525253037

Pnina Nir Study Coordinator

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Barzilai Medical Center

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 17, 2026
Registry last updated
Aug 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.